With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in ...

Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin ...

Novo Nordisk A/S (NYSE:NVO) on Monday presented data from the phase 3 REAL8 basket study investigating once-weekly Sogroya ...

In the REAL8 basket trial, Sogroya (somapacitan), administered as a once-weekly subcutaneous injection, was at least as ...

The REAL8 basket study showed Sogroya (somapacitan) was non-inferior to Norditropin (somatropin) in improving yearly growth ...

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and ...

Novo Nordisk reported positive data from a late-stage trial of its once-weekly Sogroya treatment for children with growth disorders. The Danish pharmaceutical giant said the drug was more effective ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Novo Nordisk A/S (NYSE:NVO ... The trial showed that once-weekly Sogroya was non-inferior to the once-daily growth hormone Norditropin (somatropin) in improving yearly growth rate (as measured ...